Cellromax Science셀로맥스사이언스
471820 · KOSDAQ · ₩471820 · 셀로맥스사이언스
₩3,995▲ ₩30 (0.76%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | |
|---|---|---|---|---|---|---|
| Revenue | ₩5.1B | ₩4.7B | ₩4.5B | ₩5.3B | ₩6.5B | ₩5.9B |
| Cost of sales | ₩2.3B | ₩2.2B | ₩2.7B | ₩2.6B | ₩3.3B | ₩3B |
| Gross profit | ₩2.8B | ₩2.5B | ₩1.8B | ₩2.7B | ₩3.1B | ₩2.9B |
| Operating income | ₩981M | ₩348M | ₩86M | ₩737M | ₩1.2B | ₩853M |
| Net income | ₩804M | ₩1.2B | ₩2.2B | −₩398M | ₩416M | ₩739M |
| Net income to shareholders | ₩804M | ₩1.2B | ₩2.2B | −₩398M | ₩416M | ₩739M |
Balance sheet
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | |
|---|---|---|---|---|---|---|
| Total assets | ₩51B | ₩52B | ₩51B | ₩47B | ₩48B | ₩49B |
| Current assets | ₩15B | ₩16B | ₩14B | ₩13B | ₩19B | ₩23B |
| Cash and equivalents | ₩3.4B | ₩3.2B | ₩678M | ₩5.7B | ₩2.4B | ₩1.2B |
| Total liabilities | ₩3.6B | ₩4.4B | ₩4B | ₩3.8B | ₩4.6B | ₩6.4B |
| Current liabilities | ₩2.6B | ₩3.2B | ₩2.8B | ₩3.3B | ₩3.1B | ₩4.8B |
| Borrowings | — | — | — | — | ₩1B | ₩993M |
| Total equity | ₩47B | ₩48B | ₩47B | ₩43B | ₩44B | ₩43B |
| Shareholders' equity | ₩47B | ₩48B | ₩47B | ₩43B | ₩44B | ₩43B |
Cash flow
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | |
|---|---|---|---|---|---|---|
| Cash from operations | ₩1.3B | ₩1.6B | −₩356M | −₩388M | ₩1.3B | ₩1.3B |
| Capital spending | ₩1.7M | ₩14M | ₩10M | ₩23M | ₩31M | ₩15M |
| Free cash flow | ₩1.3B | ₩1.6B | −₩366M | −₩411M | ₩1.2B | ₩1.2B |
| Dividends paid | — | — | ₩396M | ₩1.1B | — | — |
Consolidated where available. Amounts in won.
Also known as: Cellromax Science / 셀로맥스사이언스 / 471820 / KRX:471820
Source: KRX statistical information